MDXG (MiMedx Group) Tariff Resilience Score: 5/10 (As of Jul. 01, 2026)


MDXG MiMedx Group Inc MDXG
57 GF Score
Price $3.90
GF Value $6.92
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is MiMedx Group Tariff Resilience Score?

MiMedx Group MDXG +1.43% 57 Tariff Resilience Score is 5 as of Jul. 01, 2026. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.92 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,374 Biotechnology companies, MiMedx Group ranks better than 62.23% on this metric.

MiMedx Group has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

MiMedx Group has MiMedx's global supply chain and international sales expose it to tariff risks. The company is working on diversifying suppliers and enhancing pricing strategies to mitigate potential impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes MiMedx Group might have Average Resilient.

MiMedx Group  (NAS:MDXG) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

MiMedx Group Tariff Resilience Score Related Terms

MDXG vs MNPR, FTH, BBOT: Tariff Resilience Score Comparison

For the Biotechnology subindustry, MiMedx Group's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiMedx Group Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiMedx Group's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where MiMedx Group's Tariff Resilience Score falls into.


MDXG
57GF Score
MiMedx Group Inc MDXG
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
MiMedx Group (MDXG) has a Tariff Resilience Score of 5 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, MiMedx Group ranks #519 out of 1374 companies in the Biotechnology industry, placing it in the top 37.8%.
Is MiMedx Group's Tariff Resilience Score too high?
MiMedx Group's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. MiMedx Group's value of 5 is 25% above this industry median. Based on the distribution chart, MiMedx Group ranks #519 out of 1374 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Tariff Resilience Score compare to MNPR and FTH?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #519 out of 1374 companies for Tariff Resilience Score. This puts MiMedx Group in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. MiMedx Group's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.92, compared to a current price of $3.90 — trading 43.6% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Tariff Resilience Score is 5 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MiMedx Group (MDXG) Overvalued in 2026?

Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued. The current stock price of $3.90 is trading 43.6% below its estimated GF Value™ of $6.92. GuruFocus considers MiMedx Group to be Significantly Undervalued.

Key valuation signals for MDXG:

  • Tariff Resilience Score: 5
  • GF Value™: $6.92 vs. price of $3.90 (43.6% below fair value)
  • GF Score™: 57/100 with 2 warning signs
  • Industry Position: 25% above the Biotechnology median (#519 of 1374)

No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MiMedx Group Business Description

Address 1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score

Get the complete analysis for MDXG

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.90
Price
$6.92
GF Value